{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:32Z","timestamp":1790710172903,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jbspin.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T20:01:02Z","timestamp":1510689662000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-5895","authenticated-orcid":false,"given":"Marc","family":"Scherlinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Labadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bannwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mehsen-Cetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2017.10.003_bib0005","doi-asserted-by":"crossref","first-page":"vi28","DOI":"10.1093\/rheumatology\/kes278","article-title":"Evolution of treatment for rheumatoid arthritis","volume":"51","author":"Upchurch","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.2015.1090313","article-title":"Biosimilars for the management of rheumatoid arthritis: economic considerations","volume":"11","author":"Gul\u00e1csi","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211446","article-title":"update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low\/middle income countries?","author":"Misra","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-015-0155-0","article-title":"Switching between epoetins: a practice in support of biosimilar use","volume":"30","author":"D\u2019Amore","year":"2016","journal-title":"Biodrugs"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13554-013-0011-z","article-title":"Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden","volume":"3","author":"Flodmark","year":"2013","journal-title":"Biol Ther"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0030","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0035","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0045","unstructured":"SNFGE, GETAID, CREG. G., SNFGE, GETAID, CREGG. Soci\u00e9t\u00e9 nationale fran\u00e7aise de gastro-ent\u00e9rologie (SNFGE)\u00a0: information sur les infliximab biosimilaires 2015, http:\/\/www.snfge.org\/actualite\/information-sur-les-infliximab-biosimilaires."},{"key":"10.1016\/j.jbspin.2017.10.003_bib0050","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0065","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0075","first-page":"346","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0080","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double blind, non-inferiority trial","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex268","article-title":"Serum sickness-like disease after switching to biosimilar infliximab","author":"Scherlinger","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0095","first-page":"440","article-title":"The challenges of immunogenicity in developing biosimilar products","volume":"12","author":"Wadhwa","year":"2009","journal-title":"IDrugs Investig Drugs J"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0100","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","article-title":"Antibodies to infliximab in remicade-treated rheumatic patients show identical reactivity towards biosimilars","volume":"75","author":"Ruiz-Arg\u00fcello","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.10.003_bib0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in remicade-treated patients with IBD similarly recognise the biosimilar remsima","volume":"65","author":"Ben-Horin","year":"2016","journal-title":"Gut"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17301896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17301896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:24:42Z","timestamp":1761150282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X17301896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1297319X17301896"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.10.003","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}